DAIICHI SANKYO COMPANY,LIMITED (4568.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 2,953.00

From 52W high−29.73%

Volume8.97M

Market capJPY 5.43T

P/E (TTM)22.2x

P/S (TTM)2.4x

Div yield2.66%

Key dataSep 18, 2026

Open

JPY 2,953.00

From 52W high

−29.73%

Volume

8.97M

Market cap

JPY 5.43T

ValuationView details →

P/E (Fwd)

19.6x

EV/EBITDA

16.0x

P/E (TTM)

22.2x

RSI (14)

62.9

MomentumView details →

1D Return

+3.31%

YTD Return

−11.78%

ValuationView details →

P/E (Fwd)

19.6x

P/E (TTM)

22.2x

EV/EBITDA

16.0x

EV/Sales

2.4x

P/S (TTM)

2.4x

P/B (TTM)

3.2x

ProfitabilityView details →

Gross Margin

68.49%

Net Margin

12.24%

EBITDA Margin

14.44%

ROE (TTM)

15.62%

ROA (TTM)

6.49%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

+12.55%

EPS YoY

−9.71%

FCF YoY

+18.76%

Revenue CAGR 3Y

+18.42%

EPS CAGR 3Y

+35.10%

EBITDA YoY

—

MomentumView details →

1D Return

+3.31%

YTD Return

−11.78%

1Y Return

−16.64%

RSI (14)

62.9

vs 50D SMA

+6.30%

vs 200D SMA

+1.80%

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

2.42x

Quick Ratio

1.64x

Div Yield

2.66%

Div Rate

JPY 78.00

Div Growth 1Y

+30.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.12T

Net Income (TTM)

259.87B

Op. CF (TTM)

77.66B

Next earningsOct 30, 2026 →

Latest newsMore news →

The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.3d ago

Fortis Healthcare filed a special leave petition in the Supreme Court against a Delhi High Court order dated August 31 directing a forensic audit into alleged asset erosion by its former promoters during Daiichi Sankyo's enforcement proceedings.4d ago

Similar companies

Otsuka Holdings Co.,Ltd.4578.T Astellas Pharma Inc.4503.T Takeda Pharmaceutical Company Limited4502.T CHUGAI PHARMACEUTICAL CO.,LTD.4519.T Shionogi & Co.,Ltd.4507.T Eisai Co.,Ltd.4523.T Find similar companies →

Latest newsMore news →

The National Institute for Health and Care Excellence (NICE) issued a positive recommendation for reimbursement in England of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as monotherapy for adults with unresectable or metastatic HER2 Low breast cancer.3d ago Fortis Healthcare filed a special leave petition in the Supreme Court against a Delhi High Court order dated August 31 directing a forensic audit into alleged asset erosion by its former promoters during Daiichi Sankyo's enforcement proceedings.4d ago The Delhi High Court ordered a forensic audit into the dissipation of Fortis shares and assets linked to former Fortis promoters Malvinder Mohan Singh and Shivinder Mohan Singh in the Daiichi Sankyo enforcement case, appointing S Ramanand Aiyar & Co. as the forensic auditor.20d ago